This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
BioCryst Pharmaceuticals, Inc.
Drug Names(s): BCX-4208, R3421, RO5092888
Description: BCX-4208 is a transition-state purine nucleoside phosphorylase (PNP) inhibitor. PNP is involved in purine nucleoside degradation and salvage pathway (the degradative products can be converted back to the nucleosides), specifically it converts adenosine into adenine, inosine into hypoxanthine, and guanosine into guanine.
Inhibition of PNP with BCX4208 causes elevated deoxy-guanasine triphosphate, which inhibits an enzyme involved in the synthesis of deoxynucleotides. This leads to a reduction in T-, B-, and NK-cells, which are involved in immune responses.
Since PNP is involved in the metabolism of purines, inhibition can also lead to a reduction in uric acid, an end product of purine metabolism and cause of gout.
Deal Structure: In June 2000, BioCryst licensed a series of PNP inhibitors from the Albert Einstein College of Medicine (AECOM) in New York and Industrial Research Limited (IRL) of New Zealand. During 2002, BioCryst exercised the option to add a new compound, BCX-4208, to the series of inhibitors of PNP licensed from AECOM and IRL. BioCryst has worldwide exclusive rights to develop and ultimately distribute this compound and has agreed to pay certain milestone payments for future development of the drug, certain royalties on sales of any resulting product, and to share in future payments received from other third-party partners, if any. In addition, it has agreed to pay an annual license fee that is non-refundable, but is creditable against actual royalties and other payments due to AECOM and IRL.
In November 2005, Roche and BioCryst Pharmaceuticals announced an exclusive license to develop and commercialize BCX-4208. Under the terms of the agreement, Roche will obtain worldwide rights to...See full deal structure in Biomedtracker
Additional information available to subscribers only: